Rezultati - Debashis Sarker

Refine Results
  1. 1
    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics od Debra H. Josephs, Debashis Sarker

    Izdano 2015
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer od Debashis Sarker, Alison Reid, Timothy A. Yap, Johann S. de Bono

    Izdano 2009
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development od Gerhardt Attard, Debashis Sarker, Alison Reid, R. Molife, Chris Parker, Johann S. de Bono

    Izdano 2006
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials

    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials od Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor, Blair Kp McLennan, Sarah Hunter, Aneta Suder, Henrik Møller, James Spicer, Sophie Papa

    Izdano 2012
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study

    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study od Sam Sollie, Dominique S. Michaud, Debashis Sarker, Sophia N. Karagiannis, Debra H. Josephs, Niklas Hammar, Aida Santaolalla, Göran Walldius, Hans Garmo, Lars Holmberg, Ingmar Jungner, Mieke Van Hemelrijck

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer od Christophe Massard, A. Ázaro, Jean‐Charles Soria, Ulrik Lassen, Christophe Le Tourneau, Debashis Sarker, Claire Smith, U. Ohnmacht, Gerard J. Oakley, Bharvin K.R. Patel, Eunice Yuen, Karim A. Benhadji, Jordi Rodón

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor od Ruth Plummer, Divyanshu Dua, Nicola Cresti, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Perminder S. Sachdev, Bipin Mistry, Vaishali Dixit, Sharon McGonigle, Nancy Hall, Mark Matijevic, Shannon McGrath, Debashis Sarker

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer od Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji

    Izdano 2023
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours od Nicholas C. Turner, Sandra J. Strauss, Debashis Sarker, Roopinder Gillmore, Amy A. Kirkwood, A. Hackshaw, Anthie Papadopoulou, J. Bell, Irfan Kayani, Christos Toumpanakis, Federica Grillo, A Mayer, Daniel Hochhauser, Richard H. J. Beǵent, Martyn Caplin, Tim Meyer

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors od Debashis Sarker, R. Molife, T. R. J. Evans, Maryon Hardie, Cheryl Marriott, Priska Butzberger-Zimmerli, Rosemary Morrison, Judith A. Fox, Carla Heise, Sharianne G. Louie, Natasha Aziz, F. Garzon, Glenn Michelson, Ian Judson, Dalal Jadayel, Edgar Braendle, Johann S. de Bono

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer od Jessica K. Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Wu, Bruna Almeida, Nathalie Legrave, Duco S. Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorián Sopeña, James I. MacRae, Emma Nye, Michael Howell, Ambrosius P. Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, Axel Behrens

    Izdano 2022
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets

    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets od D. Britton, Yoh Zen, Alberto Quaglia, Stefan Selzer, Vikram Mitra, Christopher Lößner, Stephan Jung, Gitte Böhm, Peter Schmid, Petra Prefot, Claudia Hoehle, Saša Končarević, Julia M.W. Gee, Robert I. Nicholson, Malcolm Ward, Leandro Castellano, Justin Stebbing, Hans Dieter Zucht, Debashis Sarker, Nigel Heaton, Ian Pike

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

    1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) od Mimi I. Hu, Vivek Subbiah, Lori J. Wirth, M Schuler, Aaron S. Mansfield, Marcia S. Brose, Giuseppe Curigliano, Sophie Leboulleux, Viola W. Zhu, Bhumsuk Keam, Ignacio Matos, C-C. Lin, D.R. Adkins, Christina S. Baik, G. Lopes, Yann Godbert, Debashis Sarker, H. Zhang, Christopher D. Turner, Matthew Taylor

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanc... od Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen

    Izdano 2010
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib od Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu

    Izdano 2022
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2

    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2 od Hemant M. Kocher, Charlotte Ackerman, Garima Priyadarshini, Cheryl Lawrence, Nishtha Kotriwala, Ramona Georgescu, Rhiannon Roberts, Christine S. Hughes, Ahmet Imrali, Claude Chelala, Judith Dixon-Hughes, David K. Chang, Peter Sasieni, Pippa Corrie, Mairéad G. McNamara, Debashis Sarker, Fieke E. M. Froeling, Alan Christie, Roopinder Gillmore, Khurum Khan, David Propper

    Izdano 2025
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer od Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine S. Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David Propper

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors od Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    Izdano 2014
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial od Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S. Finn, Andrew X. Zhu

    Izdano 2022
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells od Rémi Samain, Óscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha L. George, Nicola Ferrari, Leonie KohIhammer, Sophia Lunetto, A. Senra Varela, José L. Orgaz, F Vilardell, Jorge Juan Olsina Kissler, Xavier Matías‐Guiu, Debashis Sarker, Adrian Biddle, Frances R. Balkwill, Jim Eyles, Robert W. Wilkinson, Hemant M. Kocher, Fernando Calvo, Claire M. Wells, Victoria Sanz‐Moreno

    Izdano 2023
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: